X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with Tata Investment Corporation - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs TATA INVEST. CORP. - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

TATA INVEST. CORP. 
   Change

Tata Investment Corporation is more than 70 years old. It is a non banking financial company (NBFC). The stated objective of the company is to invest in Tata and non-Tata companies, both in the listed and unlisted categories. However, investments in ... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES TATA INVEST. CORP. INDOCO REMEDIES/
TATA INVEST. CORP.
 
P/E (TTM) x 37.4 19.6 190.9% View Chart
P/BV x 2.9 2.0 149.4% View Chart
Dividend Yield % 0.8 2.2 34.8%  

Financials

 INDOCO REMEDIES   TATA INVEST. CORP.
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
TATA INVEST. CORP.
Mar-14
INDOCO REMEDIES/
TATA INVEST. CORP.
5-Yr Chart
Click to enlarge
High Rs360505 71.4%   
Low Rs249348 71.7%   
Sales per share (Unadj.) Rs119.039.6 300.9%  
Earnings per share (Unadj.) Rs8.433.8 24.7%  
Cash flow per share (Unadj.) Rs15.233.8 45.0%  
Dividends per share (Unadj.) Rs1.6017.00 9.4%  
Dividend yield (eoy) %0.54.0 13.2%  
Book value per share (Unadj.) Rs70.7390.3 18.1%  
Shares outstanding (eoy) m92.1555.10 167.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.610.8 23.8%   
Avg P/E ratio x36.412.6 289.0%  
P/CF ratio (eoy) x20.012.6 158.8%  
Price / Book Value ratio x4.31.1 394.6%  
Dividend payout %19.150.3 38.0%   
Avg Mkt Cap Rs m28,08323,489 119.6%   
No. of employees `0006.0NA-   
Total wages/salary Rs m2,16778 2,767.2%   
Avg. sales/employee Rs Th1,817.0NM-  
Avg. wages/employee Rs Th359.0NM-  
Avg. net profit/employee Rs Th127.7NM-  
INCOME DATA
Net Sales Rs m10,9682,180 503.2%  
Other income Rs m4024 168.2%   
Total revenues Rs m11,0072,203 499.6%   
Gross profit Rs m1,5652,021 77.4%  
Depreciation Rs m6331 57,527.3%   
Interest Rs m620-   
Profit before tax Rs m9092,044 44.5%   
Minority Interest Rs m0-1 0.0%   
Prior Period Items Rs m0112 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m139292 47.5%   
Profit after tax Rs m7711,863 41.4%  
Gross profit margin %14.392.7 15.4%  
Effective tax rate %15.314.3 106.8%   
Net profit margin %7.085.5 8.2%  
BALANCE SHEET DATA
Current assets Rs m5,7252,676 213.9%   
Current liabilities Rs m5,4541,188 459.1%   
Net working cap to sales %2.568.3 3.6%  
Current ratio x1.02.3 46.6%  
Inventory Days Days620-  
Debtors Days Days723 2,421.7%  
Net fixed assets Rs m5,307136 3,905.4%   
Share capital Rs m184551 33.4%   
"Free" reserves Rs m6,33116,373 38.7%   
Net worth Rs m6,51621,506 30.3%   
Long term debt Rs m1,3230-   
Total assets Rs m11,97022,736 52.6%  
Interest coverage x15.6NM-  
Debt to equity ratio x0.20-  
Sales to assets ratio x0.90.1 955.7%   
Return on assets %7.08.2 84.9%  
Return on equity %11.88.7 136.6%  
Return on capital %12.410.0 123.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5070 2,503,833.3%   
Fx outflow Rs m1,1410 2,853,500.0%   
Net fx Rs m3,3660 2,403,928.6%   
CASH FLOW
From Operations Rs m886840 105.5%  
From Investments Rs m-1,706-451 378.2%  
From Financial Activity Rs m1,316-1,032 -127.5%  
Net Cashflow Rs m497-643 -77.2%  

Share Holding

Indian Promoters % 59.2 73.0 81.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 4.5 277.8%  
FIIs % 6.0 1.5 400.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 21.0 106.7%  
Shareholders   12,805 25,758 49.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   JSW HOLDINGS  INDIABULLS FIN. SER.  INGERSOLL RAND  COX & KINGS  GEOJIT FINANCIAL SERVICES  



Today's Market

Stock Market's Sudden Crash; Rising Oil Prices; Banking Stocks and Top Cues in Action Today(Pre-Open)

The Indian share markets ended lower on Friday. The S&P BSE Sensex partially recovered after crashing 1,000 points in intraday trade to settle 280 points lower.

Related Views on News

TATA INVEST. CORP. Announces Quarterly Results (4QFY18); Net Profit Up 161.0% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, TATA INVEST. CORP. has posted a net profit of Rs 421 m (up 161.0% YoY). Sales on the other hand came in at Rs 583 m (up 62.8% YoY). Read on for a complete analysis of TATA INVEST. CORP.'s quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY18); Net Profit Up 14.3% (Quarterly Result Update)

Jun 19, 2018 | Updated on Jun 19, 2018

For the quarter ended March 2018, INDOCO REMEDIES has posted a net profit of Rs 205 m (up 14.3% YoY). Sales on the other hand came in at Rs 3 bn (down 2.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Sep 21, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - THOMAS COOK INDIA COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS